Merial is a 50% Joint Venture between Merck, Sharp and Dohme and sanofi-aventis. Merial is a world-leading animal healthcare company with a global total market share of more than 14 percent. Merial employs approximately 6,000 people worldwide and operates in more than 150 countries.
In New Zealand, Merial Ancare is the result of the merger of Merial Ltd, and the New Zealand owned Ancare NZ Ltd. The merger combined the best of two worlds, the international research capabilities of Merial and the local innovation and product development capabilities of Ancare New Zealand. Merial Ancare is New Zealand’s leading animal health company.
Merial Ancare is strong in both the production and companion animal markets with a large range of products for sheep and cattle including the IVOMEC, EPRINEX, GENESIS, ECLIPSE, MATRIX and BIONIC brands as well as FRONTLINE and PREVICOX brand for cats and dogs. The production animal products are predominantly internal and external parasite control products, but also include antibiotics, intra-mammaries, and vaccines. Merial Ancare distributes exclusively through veterinary clinics or vet associated companies.
Merial - Our Vision
We will be an innovation-driven leader in the provision of products and solutions which enhance the health, well-being, and performance of animals.
Merial - Our Values
Merial is a world-leading animal health company. We maintain our position as a world leader because we are committed to the following values:
• Focusing on the Customer
• Respecting People
• Acting with Integrity
• Promoting Innovation
• Fostering Empowerment
• Supporting Teamwork
• Committed to Performance
www.merial.com